Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C34H36N4O4.2Cl.Sn |
| Molecular Weight | 754.29 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].[Cl-].[Sn+4].CCC1=C(C)C2=CC3=C(CC)C(C)=C([N-]3)C=C4N=C(C=C5[N-]C(=CC1=N2)C(C)=C5CCC(O)=O)C(CCC(O)=O)=C4C
InChI
InChIKey=LLDZJTIZVZFNCM-UHEVNVKKSA-J
InChI=1S/C34H38N4O4.2ClH.Sn/c1-7-21-17(3)25-13-26-19(5)23(9-11-33(39)40)31(37-26)16-32-24(10-12-34(41)42)20(6)28(38-32)15-30-22(8-2)18(4)27(36-30)14-29(21)35-25;;;/h13-16H,7-12H2,1-6H3,(H4,35,36,37,38,39,40,41,42);2*1H;/q;;;+4/p-4/b25-13-,26-13-,27-14-,28-15-,29-14-,30-15-,31-16-,32-16-;;;
| Molecular Formula | Cl |
| Molecular Weight | 35.453 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C34H36N4O4 |
| Molecular Weight | 564.674 |
| Charge | -2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Sn |
| Molecular Weight | 118.71 |
| Charge | 4 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Stannsoporfin is a mesoporphyrin derivative patented by Rockefeller University as competitive heme oxygenase (HO) inhibitor for the prevention of hyperbilirubinemia in infants at risk of developing jaundice. Parenteral administration of Stannsoporfin has been shown to suppress or moderate jaundice in a wide variety of experimental and naturally occurring forms of hyperbilirubinemia in animals and man. Stannsoporfin is rapidly cleared from the plasma in animals, in adult humans, and in newborn infants and may inhibit competitive heme oxygenase for prolonged periods. The Stannsoporfin decreases the production of carbon monoxide from heme and increases the biliary excretion of unmetabolized heme but has no effect on the metabolic disposition of preformed bilirubin.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Inhibition of hippocampal heme oxygenase, nitric oxide synthase, and long-term potentiation by metalloporphyrins. | 1994 Nov |
|
| Protective role of heme oxygenase-1 induction in carbon tetrachloride-induced hepatotoxicity. | 2003 Sep 15 |
|
| Astroglial cytoprotection by erythropoietin pre-conditioning: implications for ischemic and degenerative CNS disorders. | 2005 Apr |
|
| Antioxidant mechanism of heme oxygenase-1 involves an increase in superoxide dismutase and catalase in experimental diabetes. | 2005 Aug |
|
| Heme oxygenase-2 deficiency contributes to diabetes-mediated increase in superoxide anion and renal dysfunction. | 2006 Apr |
|
| Heme oxygenase-1 enhances renal mitochondrial transport carriers and cytochrome C oxidase activity in experimental diabetes. | 2006 Jun 9 |
|
| Highly liver-specific heme oxygenase-1 induction by interleukin-11 prevents carbon tetrachloride-induced hepatotoxicity. | 2006 Oct |
|
| Nordihydroguaiaretic acid activates the antioxidant pathway Nrf2/HO-1 and protects cerebellar granule neurons against oxidative stress. | 2008 Dec 12 |
|
| Protein assay for heme oxygenase-1 (HO-1) induced by chemicals in HepG2 cells. | 2009 Dec |
|
| Mercury modulates the CYP1A1 at transcriptional and posttranslational levels in human hepatoma HepG2 cells. | 2010 Dec 15 |
|
| Overexpression of heme oxygenase-1 increases human osteoblast stem cell differentiation. | 2010 May |
|
| Arsenite down-regulates cytochrome P450 1A1 at the transcriptional and posttranslational levels in human HepG2 cells. | 2010 May 15 |
|
| In vitro inhibition of heme oxygenase isoenzymes by metalloporphyrins. | 2011 Apr |
|
| Transcriptional and posttranslational mechanisms modulating the expression of the cytochrome P450 1A1 gene by lead in HepG2 cells: a role of heme oxygenase. | 2012 Jan 27 |
|
| Inhibition of heme oxygenase-1 partially reverses the arsenite-mediated decrease of CYP1A1, CYP1A2, CYP3A23, and CYP3A2 catalytic activity in isolated rat hepatocytes. | 2012 Mar |
|
| Posttranslational mechanisms modulating the expression of the cytochrome P450 1A1 gene by methylmercury in HepG2 cells: a role of heme oxygenase-1. | 2013 Jun 7 |
|
| Increased heme-oxygenase 1 expression in mesenchymal stem cell-derived adipocytes decreases differentiation and lipid accumulation via upregulation of the canonical Wnt signaling cascade. | 2013 Mar 12 |
|
| Up-regulation of heme oxygenase-1 after infarct initiation reduces mortality, infarct size and left ventricular remodeling: experimental evidence and proof of concept. | 2014 Apr 5 |
|
| Increased HO-1 levels ameliorate fatty liver development through a reduction of heme and recruitment of FGF21. | 2014 Mar |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:48:27 UTC 2023
by
admin
on
Sat Dec 16 17:48:27 UTC 2023
|
| Record UNII |
0KAE1U0G7Q
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C471
Created by
admin on Sat Dec 16 17:48:27 UTC 2023 , Edited by admin on Sat Dec 16 17:48:27 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB04555MIG
Created by
admin on Sat Dec 16 17:48:27 UTC 2023 , Edited by admin on Sat Dec 16 17:48:27 UTC 2023
|
PRIMARY | |||
|
C152424
Created by
admin on Sat Dec 16 17:48:27 UTC 2023 , Edited by admin on Sat Dec 16 17:48:27 UTC 2023
|
PRIMARY | |||
|
DB04912
Created by
admin on Sat Dec 16 17:48:27 UTC 2023 , Edited by admin on Sat Dec 16 17:48:27 UTC 2023
|
PRIMARY | |||
|
JJ-34
Created by
admin on Sat Dec 16 17:48:27 UTC 2023 , Edited by admin on Sat Dec 16 17:48:27 UTC 2023
|
PRIMARY | |||
|
7752
Created by
admin on Sat Dec 16 17:48:27 UTC 2023 , Edited by admin on Sat Dec 16 17:48:27 UTC 2023
|
PRIMARY | |||
|
100000084977
Created by
admin on Sat Dec 16 17:48:27 UTC 2023 , Edited by admin on Sat Dec 16 17:48:27 UTC 2023
|
PRIMARY | |||
|
0KAE1U0G7Q
Created by
admin on Sat Dec 16 17:48:27 UTC 2023 , Edited by admin on Sat Dec 16 17:48:27 UTC 2023
|
PRIMARY | |||
|
106344-20-1
Created by
admin on Sat Dec 16 17:48:27 UTC 2023 , Edited by admin on Sat Dec 16 17:48:27 UTC 2023
|
PRIMARY | |||
|
C055421
Created by
admin on Sat Dec 16 17:48:27 UTC 2023 , Edited by admin on Sat Dec 16 17:48:27 UTC 2023
|
PRIMARY | |||
|
16686132
Created by
admin on Sat Dec 16 17:48:27 UTC 2023 , Edited by admin on Sat Dec 16 17:48:27 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|
